Abstract
The purpose was to evaluate and compare 5 different HER2 genetic assays with different characteristics that could affect the performance to analyze the human epidermal growth factor 2 (HER2) gene copy number under low and high throughput conditions. The study included 108 tissue samples from breast cancer patients with HER2 immunohistochemistry (IHC) results scored as 0/1+, 2+, and 3+. HER2 genetic status was analysed using chromogenic in situ hybridization (CISH) and fluorescence in situ hybridization (FISH). Scoring results were documented through digital image analysis. The cancer region of interest was identified from a serial H&E stained slide following tissue cores were transferred to a tissue microarrays (TMA). When using TMA in a routine flow, all patients will be tested for HER2 status with IHC followed by CISH or FISH, thereby providing individual HER2 results. In conclusion, our results show that the differences between the HER2 genetic assays do not have an effect on the analytic performance and the CISH technology is superior to high throughput HER2 genetic testing due to scanning speed, while the IQ-FISH may still be a choice for fast low throughput HER2 genetic testing.
1. Introduction
Human Epidermal growth factor Receptor 2 (HER2) expression is investigated routinely on all breast cancer cases to make the therapeutic decisions for patients with breast cancer. The American Society of Clinical Oncology (ASCO)/College of American Pathologist (CAP) recommendations for HER2 status testing are first immunohistochemical (IHC) staining and secondary to perform genetic HER2 testing on tissues scored as borderline cases (2+) found by IHC [1]. Ratio-based dual color HER2 gene amplification assays are commercially available from a multiple vendors using either fluorescence in situ hybridization (FISH) or chromogenic in situ hybridization (CISH), where the various tests have differing characteristics (Table 1). The HER2/neu labeled part of the dual color HER2 genetic assays is in all cases DNA based, while the centromere reference part can either be an DNA probe or an peptide nucleic acids (PNA) probe. The direct labeling of the different FISH probes from Dako and ZytoVision uses red (TexasRed), orange (Rhodamine), or green (FITC) fluorocrome, while the CISH-based assays give rise to either red, green, or blue chromogenic precipitation. Various strategies for blocking of nonspecific probe binding and detection systems have been implemented into the different HER2 genetic assays. ZytoVison uses repeat-free oligonucleotides and thereby does not need to block repeated sequences (e.g., alu, LINE, and SINE) while another system (Dako) has developed alu sequence blocking peptide nucleic acids (PNAs) to lower the background generated from the repeated sequences that are located in the HER2 DNA probe [2, 3]. A newly developed hybridization technique HER2 IQ-FISH (Dako) reduces the assay time from two days to four hours. This is achieved by breaking the hydrophobic forces in the DNA helix used in stacking [4] with the polar aprotic ethylene carbonate instead of attacking the hydrophilic hydrogen bonds between the bases that are normally broken with the use of form amide. Destabilization of the DNA helix with a polar aprotic solvent results in faster reannealing of the internal genomic repetitive sequences, thereby preventing the need for blocking of repeated sequences in the IQ-FISH assay. FISH has been regarded as the gold standard for HER2 gene copy number determination in breast cancer [5]. CISH has been introduced to simplify the evaluation of the gene signals and to be able to compare the tumour area with H&E stained slides using a conventional bright field light microscope [6]. Multiple studies have shown that tissue microarray (TMA) can be used for HER2 genetic testing and still has a high sensitivity and specificity during routine diagnostic of breast cancer [7–11]. The aims of our study were to examine the robustness of 5 different genetic HER2 assays in a high throughput routine setting using TMA containing breast cancer tissue and to evaluate if different characteristics between the five HER2 genetic assays could affect the perfomance when using digitalization of the HER2 stained slides before manually scoring on a monitor screen.
Table 1.
Different characteristics between the five HER2 genetic assays.
| Dako HER2 FISH | Dako HER2 IQ-FISH | Dako HER2 CISH | ZytoVision HER2 FISH | ZytoVision HER2 CISH | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gene | HER2 | CEN17 | HER2 | CEN17 | HER2 | CEN17 | HER2 | CEN17 | HER2 | CEN17 |
| Probe | DNA | PNA | DNA | PNA | DNA | PNA | DNA | DNA | DNA | DNA |
| Label color | TxRed | FITC | TxRed | FITC | Red | Blue | FITC | Rhodamine | Green | Red |
| Blocking reagent | alu-PNA | alu-PNA | alu-PNA | Repeat free | Repeat free | |||||
| Visualization | Fluorescence | Fluorescence | Chromogenic | Fluorescence | Chromogenic | |||||
| Hybridization reagent | Formamide | Ethylene carbonate | Formamide | Formamide | Formamide | |||||
CISH: chromogenic in situ hybridization; FISH: fluorescence in situ hybridization; PNA: peptide nucleic acids.
2. Materials and Methods
2.1. Patients
The study included 108 consecutive breast carcinomas from patients diagnosed at Herlev Hospital, Denmark, with information of HER2 status performed by IHC.
2.2. Tissue Microarray Construction (TMA)
TMAs were constructed from formalin-fixed and paraffin-embedded donor blocks, using a fully automated ATA-27 (Beecher Instrument). The areas of interest at the margin of tumor were marked on H&E stained slides by a pathologist. Four cores of 1 mm or one core of 2 mm in diameters was used per donor block and mounted in a new recipient block. Tissue preparation, microscopy, and subsequent laboratory analyses were carried out as part of the daily routine.
2.3. Chromogenic (CISH) and Fluorescent (FISH) In Situ Hybridization
The HER2 genetic testing was performed using 5 assays: HER2 CISH pharmDx Kit-SK109, HER2 FISH pharmDx Kit-K5331, HER2 IQ-FISH pharmDx-K5731 (Dako, Denmark), ZytoDot 2C SPEC HER2/CEN17 Probe Kit-C-3022-40 and SPEC HER2/CEN17 Dual Colour Probe Kit-Z-2020 (ZytoVision, Germany). The tests were conducted according to the manufacturers' instructions with minor changes, which are specified below. All samples were treated with pepsin for 8 minutes at room temperature. The last step of the ZytoDot CISH dehydration (3x 30 s in 100% ethanol and incubate 2x 30 s in xylene) was changed to air drying for 30 minutes before mounting. This preserves the red signals which can be faintly stained when using xylene or ethanol and avoids trapping of bubbles underneath the coverslip caused by water or air.
2.4. Digitalizing and Scoring
The CISH- and FISH-stained TMAs were scanned using a bright field/fluorescent panoramic scan (3D HisTech) equipped with a 40x dry objective and using single focus layer for CISH TMAs and five focus layers separated by 0.75 microns (z-stacking) for FISH TMAs. The scanned TMA full slide was analysed using Panoramic Viewer and manually scored on a computer monitor. Scores for HER2 genetic testing were counted without knowledge of patient outcome, IHC status and results from other HER2 genetic testing. Three separate tumor areas were selected and at least 60 signals (either red or green) from invasive tumor cells were counted [12]. All overlapping nuclei were excluded; only nuclei with a distinct nuclear border were being evaluated. The score was reported as the ratio between HER2 gene and centromere 17 (CEN17). Scoring criteria used for analysis were nonamplified (<1.8), equivocal (1.8–2.2), and amplified (>2.2) according to ASCO/CAP guidelines [1, 13]. For all equivocal HER2 ratios, another 60 signals were scored and the final ratio of the case was calculated from the total number of signals. The final scoring of the reanalysed equivocal HER2 ratios was reported according to the cut-off criteria nonamplified (<2.0) and amplified (≥2.0).
2.5. Statistic
The statistical analysis of the accuracy was performed by calculating the agreement between a constructed consensus assay from the five different HER2 genetic assays and κ statistics [14].
3. Results
A total of 108 breast carcinomas were included in the study and 5 different HER2 genetic assays (FISH n = 3, CISH n = 2) were investigated, resulting in 540 scoring results. The success rate of FISH and CISH HER2 genetic testing during routine condition was 100%. The scanning success was 97,6% (527 out of 540). Thirteen samples failed; of those FISH accounted for 11 samples and CISH accounted for 2 samples. Failures of FISH scanning were missing autofocus, high background staining, and persistent autofluorescence. Failures of CISH scanning for the two samples were caused by a fingerprint and an air bobble captured underneath the coverslip. These 13 patients were excluded (n = 65 scoring results), resulting in a total cohort of evaluated patients of 95 (n = 475 scoring results). All thirteen scanning failures were located on the 2 mm core TMA's, while at least two of the four cores on the 1 mm core TMA could be scanned and analysed successfully. The mean digital imaging scanning time of CISH using a 40x objective was 29 sec per mm2, while the FISH stained slides using five extended focus layers for the HER2 and CEN17 filters and a single layer for DAPI were 764 sec/mm2.
When using the mean HER2 ratio of CISH and FISH scores, concordance was found in 99% (94/95) of the cases (Cohen κ coefficient, 0,9664), which support earlier published results [12, 14, 15] (Table 2). One tissue core was scored as nonamplified by CISH (ratio = 1.9) and amplified by FISH (ratio = 2.3). We observed high concordance between the different FISH and CISH assays when a single assay was compared to a consensus generated scoring of the remaining four HER2 genetic assays. The concordance within the CISH assays was 97.9% and 99.0% (Tables 3(a) and 3(b)), while the concordance within the FISH assays were 97.9%, 97.9%, and 99.0% (Tables 3(c), 3(d), and 3(e)), respectively.
Table 2.
Performance of mean CISH and mean FISH HER2 ratio assay.
| CISH | FISH | ||
|---|---|---|---|
| Amplified (≥2.0) | Nonamplified | Total | |
| Amplified (≥2.0) | 18 | 0 | 18 |
| Nonamplified | 1 | 76 | 77 |
| Total | 19 | 76 | 95 |
CISH: chromogenic in situ hybridization; FISH: fluorescence in situ hybridization; CI: confidence interval. Concordance, 99,0%; Cohen κ coefficient, 0,9664 (95% CI, 0,9010–1,0000).
Table 3.
Concordance between one analysis against the mean result of the other four assays used.
(a)
| Consensus (mean of the other four assays) | CISH ZytoVision |
||
|---|---|---|---|
| Amplified (≥2.0) | Nonamplified | Total | |
| Amplified (≥2.0) | 18 | 1 | 19 |
| Nonamplified | 1 | 75 | 76 |
| Total | 19 | 76 | 95 |
Concordance, 97,9%; Cohen κ coefficient, 0,9342.
(b)
| Consensus (mean of the other four assays) | CISH Dako | ||
|---|---|---|---|
| Amplified (≥2.0) | Nonamplified | Total | |
| Amplified (≥2.0) | 18 | 1 | 19 |
| Nonamplified | 0 | 76 | 76 |
| Total | 18 | 77 | 95 |
Concordance, 99,0%; Cohen κ coefficient, 0,9664.
(c)
| Consensus (mean of the other four assays) | FISH ZytoVision |
||
|---|---|---|---|
| Amplified (≥2.0) | Nonamplified | Total | |
| Amplified (≥2.0) | 18 | 1 | 18 |
| Nonamplified | 1 | 76 | 77 |
| Total | 19 | 76 | 95 |
Concordance, 97,8%; Cohen κ coefficient, 0,9664.
(d)
| Consensus (mean of the other four assays) | FISH Dako |
||
|---|---|---|---|
| Amplified (≥2.0) | Nonamplified | Total | |
| Amplified (≥2.0) | 18 | 0 | 18 |
| Nonamplified | 2 | 75 | 77 |
| Total | 20 | 75 | 95 |
Concordance, 97,9%; Cohen κ coefficient, 0,9343.
(e)
| Consensus (mean of the other four assays) | IQ-FISH Dako |
||
|---|---|---|---|
| Amplified (≥2.0) | Nonamplified | Total | |
| Amplified (≥2.0) | 17 | 1 | 18 |
| Nonamplified | 0 | 77 | 77 |
| Total | 17 | 78 | 95 |
Concordance, 99,0%; Cohen κ coefficient 0,9650.
CISH: chromogenic in situ hybridization; FISH: fluorescence in situ hybridization.
Discordant HER2 ratio scoring results of the FISH and CISH assays were found in 6% of the patients (Table 4). In case 15 three assays showed nonamplification while two assays showed amplified HER2/CEN17 ratio. The scorings were very close to the borderline indicated by four of the assays while one (FISH, Dako) showed 3.0 HER2/CEN17 ratio amplification. An explanation for this difference is that it may be caused by tumour heterogeneous amplification, as a region on the 2 mm core were clearly HER2 amplified. Case 69, four assays showed amplification and one FISH assay showed nonamplification. The divergent scoring results may be due to tumour heterogeneous amplification, where the correct amplified tumour area was not identified on the 2 mm core. With cases 48 and 84, the scorings were very close to the borderline indicated by HER2/CEN17 ratio amplification close to 2.0. The IHC scores were 2+ and 1+, respectively (Table 4). This indicates that true borderline cases cannot be solved either by FISH, CISH, or IHC. Case 74: four assays showed non-amplification and one FISH assay showed amplification. The faint green signals from the CEN17 probe may be the reason as it causes an underestimation of the amount of signals. Case 90: four assays showed amplification and one CISH assay showed non-amplification. The finding is due to cluster amplification where the red chromogenic staining gave a purple colour and thereby could be misread as a blue colour.
Table 4.
Discrepancy cases between the five different HER2 genetic ratio assays.
| CISH ZytoVision |
CISH Dako |
FISH ZytoVision |
FISH Dako |
IQ-FISH Dako |
IHC HER2 |
|
|---|---|---|---|---|---|---|
| Case 15 | 1,7 | 2,1 | 1,9 | 3,0 | 1,9 | 2+ |
| Case 48 | 2,1 | 2,1 | 2,1 | 2,3 | 1,9 | 2+ |
| Case 69 | 3,7 | 4,8 | 7,1 | 7,2 | 1,4 | 2+ |
| Case 74 | 1,5 | 1,2 | 1,6 | 2,2 | 1,6 | 1+ |
| Case 84 | 2,0 | 1,4 | 2,0 | 1,9 | 1,8 | 1+ |
| Case 90 | 2,9 | 1,9 | 2,4 | 2,4 | 3,7 | 2+ |
CISH: chromogenic in situ hybridization; FISH: fluorescence in situ hybridization.
4. Discussion
HER2 testing is required to identify of breast cancer patients that may benefit for trastuzumab adjuvant therapy. Significant correlation in HER2 status between dual-colour CISH and FISH analysis is reported as well as a reduction in scoring time and laboratory hands on time [7, 9, 16–18]. The mean dual-colour CISH HER2 copy number and the mean HER2/CEN17 ratio were lower than those estimated with FISH but did not result in discrepancy of the final result. The number of HER2 counted signals can be underestimated due to overlapping signals. This discrepancy is only a risk in low amplified cases and in our study it was only seen in heavily amplified HER2 signals.
Introduction of TMA into a clinical routine laboratory can be a useful technique when a high throughput of HER2 analyses is needed. By using TMA, an additional possibility emerges to analyse all patients with regard to both IHC HER2 and HER2 genetic status without considerable increase of cost [7].
In most tumours, the HER2/CEN17 is homogeneously amplified; however in approximately 10% of the carcinomas, HER2 genetic testing shows unusual signal pattern [19, 20]. We identified three different HER2 amplification staining patterns. Homogeneously amplified tumors with identical results in scored areas, intratumour heterogeneous amplification/nonamplification areas, in which a minimum of one region was scored as amplified and another scored nonamplified and can be considered as hot spot. A third heterogeneous amplification pattern was illustrated by a single cell with extensive amplification surrounded by cells that are nonamplified. However, little is known about the clinical implication of such patterns, except for one study demonstrating intratumour heterogeneity of HER2 gene amplification to be associated with a shorter disease-free survival [20]. We used 4 cores from different areas in the periphery of the carcinoma and found that all cores should be included in the counting of dots to get a correct result.
The different use of DNA and PNA probes together with different blocking reagents against repeated regions did not affect the genetic test results.
To our knowledge, the first study to analyse the difference between CISH and FISH for high throughput HER2 genetic testing aimed at identifying the best technique for preparation of digital imaging and scanning. The high level of agreement obtained between CISH and FISH genetic testing with respect to assay performance makes the two techniques equivalent, in a technical perspective. The most important advantage of CISH over FISH is the much faster digitalization of a CISH-stained slide in combination with low failure rate. The success of CISH digitalization is an advantage for a future automatic image analysis of HER2 genetic testing in a routine laboratory.
5. Conclusion
In conclusion, our results show that the differences between the five HER2 genetic assays do not have effect on the analytic performance and the CISH technology is superior to high throughput HER2 genetic testing due to scanning speed, while the IQ-FISH may still be a choice for fast low throughput HER2 genetic testing when only analysis of a few patients is required.
Acknowledgments
The authors acknowledge Nordic BioSite and Dako for providing the reagents for this study. The authors declare that there is no conflict of interests regarding the publication of this paper.
References
- 1.Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Archives of Pathology and Laboratory Medicine. 2007;131(1):18–43. doi: 10.5858/2007-131-18-ASOCCO. [DOI] [PubMed] [Google Scholar]
- 2.Mayr D, Heim S, Weyrauch K, et al. Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology. 2009;55(6):716–723. doi: 10.1111/j.1365-2559.2009.03427.x. [DOI] [PubMed] [Google Scholar]
- 3.Nielsen KV, Müller S, Poulsen TS, Gabs S, Schonau A. Chapter 11: combined use of PNA and DNA for fluorescence in situ hybridization (FISH) In: Nielsen PE, Egholm M, editors. Peptide Nucleic Acids: Protocols and Applications. 2nd edition. Norfolk, UK: Horizon Bioscience; 2004. pp. 227–260. [Google Scholar]
- 4.Hansen CM. Hansen Solubility Parameters: A User's Handbook. 2nd edition. Taylor & Francis; 2007. Chapter 14: applications–environmental stress cracking in polymers; pp. 269–292. [Google Scholar]
- 5.Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13(1):63–72. [PubMed] [Google Scholar]
- 6.Tanner M, Gancberg D, Leo BAD, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. The American Journal of Pathology. 2000;157(5):1467–1472. doi: 10.1016/S0002-9440(10)64785-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Rossing HH, Talman M-LM, Lænkholm A-V, Wielenga VT. Implementation of TMA and digitalization in routine diagnostics of breast pathology. APMIS. 2012;120(4):341–347. doi: 10.1111/j.1600-0463.2011.02871.x. [DOI] [PubMed] [Google Scholar]
- 8.Dekker TJA, Borg ST, Hooijer GKJ, et al. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. 2012;120:341–347. doi: 10.1186/bcr3208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Park K, Kim J, Lim S, Han S, Lee JY. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Modern Pathology. 2003;16(9):937–943. doi: 10.1097/01.MP.0000086487.78558.7D. [DOI] [PubMed] [Google Scholar]
- 10.Francis GD, Jones MA, Beadle GF, Stein SR. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagnostic Molecular Pathology. 2009;18(2):88–95. doi: 10.1097/PDM.0b013e31816f6374. [DOI] [PubMed] [Google Scholar]
- 11.Graham AD, Faratian D, Rae F, Thomas JSJ. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology. 2008;52(7):847–855. doi: 10.1111/j.1365-2559.2008.03047.x. [DOI] [PubMed] [Google Scholar]
- 12.Olsen KE, Knudsen H, Rasmussen BB, et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncologica. 2004;43(1):35–42. doi: 10.1080/02841860310019007. [DOI] [PubMed] [Google Scholar]
- 13.Gong Y, Sweet W, Duh Y-J, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer a multicenter study using conventional scoring criteria and the new asco/cap recommendations. American Journal of Clinical Pathology. 2009;131(4):490–497. doi: 10.1309/AJCPI00TVGIGYXAA. [DOI] [PubMed] [Google Scholar]
- 14.Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–174. [PubMed] [Google Scholar]
- 15.Mayr D, Heim S, Weyrauch K, et al. Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology. 2009;55(6):716–723. doi: 10.1111/j.1365-2559.2009.03427.x. [DOI] [PubMed] [Google Scholar]
- 16.García-Caballero T, Grabau D, Green AR, et al. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European Multicentre Study involving 168 specimens. Histopathology. 2010;56(4):472–480. doi: 10.1111/j.1365-2559.2010.03503.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Gupta D, Middleton LP, Whitaker MJ, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. American Journal of Clinical Pathology. 2003;119(3):381–387. doi: 10.1309/p40p2ead42pukdmg. [DOI] [PubMed] [Google Scholar]
- 18.Jacquemier J, Spyratos F, Esterni B, et al. SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer. 2013;13:351–361. doi: 10.1186/1471-2407-13-351. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Seol H, Lee HJ, Choi Y, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Modern Pathology. 2012;25:938–948. doi: 10.1038/modpathol.2012.36. [DOI] [PubMed] [Google Scholar]
- 20.Starczynski J, Atkey N, Connelly Y, et al. HER2 gene amplification in breast cancer: a rogues’ gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. American Journal of Clinical Pathology. 2012;137(4):595–605. doi: 10.1309/AJCPATBZ2JFN1QQC. [DOI] [PubMed] [Google Scholar]